Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $5.3 million.

  • Intellia Therapeutics' Gains from Investment Securities rose 37932.68% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 2230.56%. This contributed to the annual value of $5.4 million for FY2024, which is 84.65% down from last year.
  • Per Intellia Therapeutics' latest filing, its Gains from Investment Securities stood at $5.3 million for Q3 2025, which was up 37932.68% from $5.4 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Gains from Investment Securities high stood at $171.3 million for Q3 2021, and its period low was $100000.0 during Q1 2023.
  • Its 5-year average for Gains from Investment Securities is $23.6 million, with a median of $5.9 million in 2022.
  • In the last 5 years, Intellia Therapeutics' Gains from Investment Securities soared by 1893333.33% in 2021 and then crashed by 9831.63% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Gains from Investment Securities (Quarter) stood at $6.2 million in 2021, then soared by 307.31% to $25.3 million in 2022, then crashed by 95.2% to $1.2 million in 2023, then skyrocketed by 8960.36% to $109.7 million in 2024, then tumbled by 95.19% to $5.3 million in 2025.
  • Its Gains from Investment Securities stands at $5.3 million for Q3 2025, versus $5.4 million for Q2 2025 and $5.9 million for Q1 2025.